Valuation: Sanofi

Market Cap 86.26B 98.1B 81.58B 74B 139B 9,416B 140B 976B 377B 4,805B 368B 360B 15,439B P/E 2026 *
11.5x
P/E 2027 * 9.99x
Enterprise Value 97.72B 111B 92.43B 83.83B 158B 10,667B 158B 1,106B 427B 5,443B 417B 408B 17,490B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.87x
Free-Float
88.34%
Yield 2026 *
5.91%
Yield 2027 * 6.24%
1 day+0.15%
1 week-3.07%
Current month-6.45%
1 month-6.47%
3 months-3.59%
6 months-13.00%
Current year-13.31%
1 week 71
Extreme 71
74.45
1 month 71
Extreme 71
77.59
Current year 71
Extreme 71
85.4
1 year 71
Extreme 71
90.46
3 years 71
Extreme 71
110.02
5 years 71
Extreme 71
110.02
10 years 63.1
Extreme 63.1
110.02
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer - 01/09/2026
Director TitleAgeSince
Director/Board Member 61 30/04/2019
Director/Board Member 56 28/04/2020
Director/Board Member 65 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%-3.07% - - 98.02B
+0.11%+2.76%+63.52%+115.51% 1,055B
+0.27%+0.73%+51.33%+73.10% 654B
+0.73%+0.88%+20.70%+73.89% 467B
-1.36%-0.39%+40.20%+41.03% 348B
+1.34%+5.47%+23.37%+31.30% 275B
-0.48%-0.06%+13.56%+12.36% 258B
+0.85%+8.42%+53.17%+55.45% 224B
+0.85%+1.40%+35.78%+101.47% 187B
-0.30%-10.41%-27.62%-61.04% 171B
Average +0.14%+0.74%+30.45%+49.23% 404.26B
Weighted average by Cap. +0.12%+1.32%+40.69%+69.05%

Financials

2026 *2027 *
Net sales 47.65B 54.19B 45.07B 40.88B 76.8B 5,201B 77.2B 539B 208B 2,654B 203B 199B 8,528B 50.64B 57.6B 47.9B 43.45B 81.63B 5,528B 82.05B 573B 221B 2,821B 216B 211B 9,064B
Net income 7.48B 8.51B 7.07B 6.42B 12.05B 816B 12.12B 84.63B 32.68B 417B 31.91B 31.22B 1,339B 8.89B 10.11B 8.4B 7.62B 14.32B 970B 14.4B 101B 38.83B 495B 37.92B 37.1B 1,590B
Net Debt 11.46B 13.04B 10.84B 9.83B 18.48B 1,251B 18.57B 130B 50.09B 639B 48.92B 47.86B 2,052B 8.34B 9.48B 7.88B 7.15B 13.44B 910B 13.5B 94.33B 36.43B 464B 35.57B 34.8B 1,492B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
28/09/26 €71.97 +0.15% 704
25/09/26 €71.86 -0.66% 3,073
24/09/26 €72.34 -1.32% 3,145
23/09/26 €73.31 -0.61% 726
22/09/26 €73.76 -0.22% 2,935
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
72.00EUR
Average target price
94.06EUR
Spread / Average Target
+30.64%

Quarterly revenue - Rate of surprise